Arlo-cel Registrational Study Meets Response Endpoints
Bristol Myers Squibb said the registrational Phase II QUINTESSENTIAL study of arlocabtagene autoleucel met its primary overall-response-rate endpoint and key complete-response-rate endpoint in quadruple-class-exposed relapsed or refractory multiple myeloma after at least four prior…
